Clinical Momentum Builds

The new foundation model proves reproducible across more participants and tasks, making Neuralink's BCI look less like a one-off demonstration and more like a clinical platform. Regulators remain cautious, but the company gains credibility with hospitals, patient groups, and disability-focused researchers.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.